Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
Joseph E. Grossman, Divya Vasudevan, Cailin E. Joyce, Manuel Hildago
Abstract
Table 1 Anti-PD-1 monotherapy approvals with PD-L1 companion diagnostic. Clinical trials for which only PD-L1+ patients were treated Keytruda in 1L NSCLC KEYNOTE-024 Tecentriq in 1L NSCLC IMpower110 Clinical trials for which relatively few PD-L1-patients were assessed Keytruda in chemotherapy-resistant cervical cancer 16% PD-L1-pts (N = 16) KEYNOTE-158 (Cohort E) Clinical trials demonstrating limited benefit in PD-L1-patients Keytruda in 2L+ esophageal 1endpoint met only in PD-L1 selected pts KEYNOTE-181 Keytruda in 1L SCCHN No benefit vs cetuximab in PD-L1 unselected pts KEYNOTE-048 Keytruda in 1L urothelial cancer Less benefit vs platinum-based chemo in PD-L1-pts KEYNOTE-052 KEYNOTE-361 Tecentriq in 1L urothelial cancer pts who are ineligible for platinum-based chemo Less benefit vs platinum-based chemo in PD-L1-pts IMvigor210 IMvigor130